Emodin induces apoptosis in human prostate cancer cell LNCaP

Asian Journal of Andrology

Volumn 10, Issue 4, 2008, Pages 625-634

  Yu, Chun Xiao ^a   Zhang, Xiao Qian ^b   Kang, Lu Dong ^a   Zhang, Peng Ju ^a   Chen, Wei Wen ^a   Liu, Wen Wen ^a   Liu, Qing Wei ^c   Zhang, Jian Ye ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Global Medical Affairs Merck Sharp Dohme China   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Androgen receptor; Apoptosis; Emodin; LNCaP; Mitochondrial pathway; p53; PC 3; Proliferation; Prostate cancer

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANDROGEN RECEPTOR; CASPASE 3; CASPASE 8; CASPASE 9; DNA; EMODIN; FAS ANTIGEN; FAS LIGAND; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53;

AGAR GEL ELECTROPHORESIS; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL ASSAY; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA FRAGMENTATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INHIBITION KINETICS; MALE; MITOCHONDRION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ADENOCARCINOMA; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; EMODIN; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ANDROGEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 45849096124     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1111/j.1745-7262.2008.00397.x     Document Type: Article

References (40)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. The prostate: An increasing medical problem. Prostate 1990; 16: 39-48.
2. Hanks GE. Long-term control of prostate cancer with radiation. Past, present, and future. Urol Clin N Am 1996; 23: 605-16.
3. Garnick MB. Hormonal therapy in the management of prostate cancer: From Higgins to the present. Urology 1997; 49: 5-15.
4. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003; 3: 768-80.
5. Zhang HN, Yu CX, Zhang PJ, Chen WW, Jiang AL, Kong F, et al. Curcumin downregulates homeobox gene NKX3.1 in prostate cancer cell LNCaP. Acta Pharmacol Sin 2007; 28: 423-30.
6. Tsai TH, Chen CF. Ultraviolet spectrum identification of emodin in rabbit plasma by HPLC and its pharmacokinetics application. Asia Pac J Pharmacol 1992; 7: 53-6.
7. Liang JW, Hsiu SL, Huang HC, Lee-Chao PD. HPLC analysis of emodin in serum, herbs and Chinese herbal prescriptions. J Food Drug Anal 1993; 1: 251-7.
8. Koyama M, Kelly TR, Watanabe KA. Novel type of potential anticancer agents derived from chrysophanol and emodin. Some structure-activity relationship studies. J Med Chem 1988; 31: 283-4.
9. + -ATPase of the rabbit renal medulla and their diuretic action. Yao Xue Xue Bao 1988; 23: 17-20.
10. Huang HC, Chu SH, Chao PD. Vasorelaxants from Chinese herbs, emodin and scoparone, possess immunosuppressive properties. Eur J Pharmacol 1991; 198: 211-3.
11. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis. Science 1997; 275: 1132-6.
12. Hovenian MS, Deming CL. The heterologous growth of cancer of the human prostate. Surg Gynecol Obstet 1948; 86: 29-35.
13. Ross RK, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B. Serum testosterone levels in young black and white men. J Natl Cancer Inst 1986; 76: 45-8.
14. Vogelstein B, Lane D, Levine, AJ. Surfing the p53 network. Nature 2000; 408: 307-10.
15. Prives C, Hall PA. The p53 pathway. J Pathology 1999; 187: 112-26.
16. Vousden KH. p53: Death star. Cell 2000; 103: 691-4.
17. Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alenmri ES. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell 1998; 1: 949-57.
18. Sun XM, Macfarlane M, Zhuang J, Wolf BB, Green DR, Cohen GM. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J Biol Chem 1999; 274: 5053-60.
19. Adams JM, Cory S. The Bcl-2 protein family: Arbiters of cell survival. Science 1998; 281: 1322-6.
20. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, et al. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked. Science 1997; 275: 1129-32.
21. Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA 1998; 95: 4997-5002.
22. Huang Q, Shen HM, Shui GH, Wenk MR, Ong CN. Emodin inhibits tumor cell adhesion through disruption of the membrane lipid raft-associated integrin signaling pathway. Cancer Res 2006; 66: 5807-15.
23. Fu ZY, Han JX, Huang HY. Effects of emodin on gene expression profile in small cell lung cancer NCI-H446 cells. Chin Med J 2007; 120: 1710-5.
24. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002; 62: 1008-13.
25. Mitchell SH, Zhu W, Young CY. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res 1999; 59: 5892-5.
26. Xing N, Chen Y, Mitchell SH, Young CY. Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis 2001; 22: 409-14.
27. He ML, Yuan HQ, Jiang AL, Gong AY, Chen WW, Zhang PJ, et al. Gum mastic inhibits the expression and function of the androgen receptor in prostate cancer cells. Cancer 2006; 106: 2547-55.
28. Biancolella M, Valentini A, Minella D, Vecchione L, D'Amico F, Chillemi G, et al. Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines. Invest New Drugs 2007; 25: 491-7.
29. Valentini A, Biancolella M, Amati F, Gravina P, Miano R, Chillemi G, et al. Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line. Drug Metab Dispos 2007; 35: 968-72.
30. Cleutjens K, Vander KH, Van EC, Van RH, Faber PW, Trapman J. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol 1997; 11: 148-61.
31. Cleutjens K, Van EC, Vander KH, Brinkman AO, Trapman J. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate specific antigen promoter. J Biol Chem 1996; 271: 6379-88.
32. Chen X, Barqonetti J, Prives C. p53, through p21 (WAF1/CIP1), induces cyclin D1 synthesis. Cancer Res 1995; 55: 4257-63.
33. Colman MS, Afshari CA, Barrett JC. Regulation of p53 stability and activity in response to genotoxic stress. Mutat Res 2000; 462: 179-88.
34. Winters ZE. P53 pathways involving G2 checkpoint regulators and the role of their subcellular localization. J R Coll Surg Edinb 2002; 47: 591-8.
35. Green DR, Bissonnette RP, Cotter TG. Apoptosis and cancer. Important Adv Oncol 1994; 11: 37-52.
36. Hsu SL, Yin SC, Liu MC, Reichert U, Ho WL. Involvement of cyclin-dependent kinase activities in CD437-induced apoptosis. Exp Cell Res 1999; 252: 332-41.
37. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 1997; 3: 614-20.
38. Strobel T, Swanson L, Korsmeyer S, Cannistra SA. Bax enhances paclitaxel-induced apoptosis through a p53-inde-pendent pathway. Proc Natl Acad Sci USA 1996; 93: 14094-9.
39. Huang J, Wu LJ, Tashiro S, Onodera S, Ikejima T. Bcl-2 up-regulation and P-p53 down-regulation account for the low sensitivity of murine L929 fibrosarcoma cells to oridonin-induced apoptosis. Biol Pharm Bull 2005; 28: 2068-74.
40. Cohen GM. Caspases: The executioners of apoptosis. Biochem J 1997; 326: 1-16.